Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel

Autor: Ahmad Awada, Jan B. Vermorken, J. R. Germà-Lluch, Ioannis S. Pateras, Amanda Psyrri, M. Degardin, Christos Kroupis, Catherine Fortpied, Margaritis Avgeris, Heinz Roland Kienzer, Jessica Menis, George Koutsodontis, L. Herman, Nikolaos Goutas, Lisa Licitra, Johannes A. Langendijk, Livia Giurgea, Éva Remenár, C.M.L. van Herpen

Publikováno v: Annals of Oncology, 28, 2213-2218
Annals of Oncology, 28(9), 2213-2218. Oxford University Press
Annals of Oncology, 28, 9, pp. 2213-2218
Annals of oncology
Annals of oncology, 28 (9

Background: EORTC 24971 was a phase III trial demonstrating superiority of induction regimen TPF (docetaxel, cisplatin, 5-fluorouracil) over PF (cisplatin/5-fluorouracil), in terms of progression-free (PFS) and overall survival (OS) in locoregionally

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd6701d228c2eaa29cb0f91718f1f4ba
https://doi.org/10.1093/annonc/mdx320